Cargando…

CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma (MM) is an incurable disease for which novel therapeutic approaches targeting the malignant cells and the associated bone disease are urgently needed. CK1α is a protein kinase that plays a crucial role in the signaling network that sustains plasma cell (PC) survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fregnani, Anna, Saggin, Lara, Gianesin, Ketty, Quotti Tubi, Laura, Carraro, Marco, Barilà, Gregorio, Scapinello, Greta, Bonetto, Giorgia, Pesavento, Maria, Berno, Tamara, Branca, Antonio, Gurrieri, Carmela, Zambello, Renato, Semenzato, Gianpietro, Trentin, Livio, Manni, Sabrina, Piazza, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454895/ https://www.ncbi.nlm.nih.gov/pubmed/36077711 http://dx.doi.org/10.3390/cancers14174173

Ejemplares similares

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
por: Manni, S., et al.
Publicado: (2022)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma
por: Carrino, Marilena, et al.
Publicado: (2019)

Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
por: Spinello, Zaira, et al.
Publicado: (2021)

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research
por: Manni, Sabrina, et al.
Publicado: (2020)

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
por: Piazza, Francesco, et al.
Publicado: (2010)

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
por: Manni, Sabrina, et al.
Publicado: (2013)

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
por: Canovas Nunes, Sara, et al.
Publicado: (2018)

CK2β Regulates Hematopoietic Stem Cell Biology and Erythropoiesis
por: Quotti Tubi, Laura, et al.
Publicado: (2023)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

P1111: WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN ACADEMIC CENTER
por: Danesin, Nicolò, et al.
Publicado: (2023)

Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
por: Danesin, Nicolò, et al.
Publicado: (2023)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

CK2β-regulated signaling controls B cell differentiation and function
por: Quotti Tubi, Laura, et al.
Publicado: (2023)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
por: Zambello, Renato, et al.
Publicado: (2014)

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE
por: Massarotti, L., et al.
Publicado: (2023)

Metabolic control of epigenetic rearrangements in B cell pathophysiology
por: Calciolari, Beatrice, et al.
Publicado: (2022)

Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
por: Piazza, Francesco, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia
por: Teramo, Antonella, et al.
Publicado: (2020)

Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options
por: Calabretto, Giulia, et al.
Publicado: (2021)

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
por: Manni, Sabrina, et al.
Publicado: (2018)

STAT3 mutation impacts biological and clinical features of T-LGL leukemia
por: Teramo, Antonella, et al.
Publicado: (2017)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
por: Bacci, Christian, et al.
Publicado: (2021)

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
por: Zambello, Renato, et al.
Publicado: (2018)

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2018)

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder Really Two Distinct Diseases?
por: Zambello, Renato, et al.
Publicado: (2014)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth
por: Pizzi, Marco, et al.
Publicado: (2015)

HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen
por: Frezzato, Federica, et al.
Publicado: (2012)

Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia
por: Mariotti, Barbara, et al.
Publicado: (2020)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i4r0khvf2a02tq9q0d4at94ssc